LATEST PRESS RELEASE
Amorfix appoints Dr. Elliot Goldstein and Mr. Warren Whitehead to Board of Directors
September 4, 2014
Amorfix announces retirement of Dr. Hans Black
August 20, 2014
Amorfix announces Annual Meeting, Record Date and Adopts Advance Notice By-Law
August 14, 2014
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.
Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.